



MARKET ACCESS
SEMINÁRE A RIEŠENIA

Health care & Market access in practice

Central European Patient Access Seminar

8.11.2016

Austria Trend Hotel Bratislava, Vysoká 2A, 811 06 Bratislava, Slovakia

www.austria-trend.sk

PROGRAM

8:00 - 9:00

Registration

9.00 – 9.15

Seminar opening

09.15 – 10.00

Reassessment of drugs and medical technologies – does it influence patient access?

Dominik Tomek

Abstract: Slovakia is discussing a reassessment of drugs and medical technologies with possible reimbursement consequences. Do we have the potential to do this task objectively and professionally? What can be the consequences on patient access? We need horizon scanning to do reassessment properly. Do we have the resources? How to make drug assessment more objective and where is the role of patients? The objective of this presentation is to show some theory and examples from the world and to discuss the implication and impact in the Slovakian setting.

10.00 – 11.15

Treatment adherence and its impact on patient access

Tamás Ágh

Abstract: Market Access has undergone a fundamental shift from a company-centered to a patient-centered approach which aims to ensure access for those patients who can optimally benefit from a product. This also means that in the evaluation process of new technologies patient reported outcomes have more and more crucial role. Currently, health-related quality of life is a significant factor in the measurement of health gain to support pricing and reimbursement decisions.

In addition, a new technology can generate health gain only if patients use it; thus, in this patient access mindset, treatment adherence also plays a key role. The objective of this presentation is (i) to provide a short overview on the key terms, definitions, measurement methods and determinants of adherence and consequences of non-adherence, and (ii) to describe how patient adherence can be considered during drug development and for the market access strategy of an innovative medicine. Specific case studies will be presented to put the different aspects of patient adherence to real-life perspective.

11.15 – 11.45

Coffee Break

11.45 – 12.30

Patient Access to innovative medicines and medical technologies in the EU from the Patients perspective.

Nicola Bedlington

Patients' vision is that all patients with chronic and/or lifelong conditions in the EU have access to high quality, patient-centered equitable health and social care. Timely access to accurate diagnosis and appropriate treatment not only improves patient health and well-being but can also offset significant costs to the health and social systems as a result of avoidable exacerbation of the health condition. For patients with chronic diseases, medicines form an important, sometimes crucial, aspect of treatment. Innovative medicines hold the promise of cure or at least significant improvement to health or quality of life. Scientific knowledge is advancing very fast. New, potentially ground-breaking discoveries are being made, including in personalized medicine and genomics. Industry is increasingly focusing on developing differentiated and specialized medicines targeted at smaller patient groups. Patients will only reap the benefits of the new therapies if, once they are on the market, they are accessible and affordable to all who need them. Access to medicines can be framed in similar terms as access to healthcare generally, on the principle of "equitable access based on needs not means": Availability: the medicine needs to be available in the market, Affordability: patients should not suffer financial hardship as a result of seeking treatment, Adequacy: the medicine should be safe, of high quality and effective, Appropriateness: the medicine needs to be appropriate for patients' needs, Accessibility: the medicine should be distributed through reachable channels, without geographical or time barriers.

12.30 – 13.00

Discussion

13.00 – 14.00

Lunch

14.00 – 15.15

Patient Access in the CEEC

Stanimir Hasurdjiev

The goal of the presentation is to identify the main challenges to patients in order to establish the priorities for tackling inequalities, to determine to what extent the problems in the health systems in the old Members States match the problems of the new ones as well as to acquire sensible data on patients' perspective on the issue. Based on collected data, presentation identifies common and country-specific concerns for patient's access to health care. With respect to the common concerns of patients, will the author emphasize the lack of equal and timely access to treatment, of life-long range of services and support for patients with chronic diseases and of thorough information on the possibilities for treatment abroad, the limited and unequal access to modern treatment as well as the increased financial burden for patients. With respect to the work of non-governmental organizations, patients believe that they have to improve the communication channels between stakeholders and their advocacy skills with respect to access to treatment and inclusion of new medication. As to the current EU priorities, the presentation points out that there is a lack of quality information on the possibilities for treatment abroad, ignorance with respect to pharmacovigilance, limited number of clinical trials and insufficient transparency on medication policies. The case of Bulgaria is to illustrate that inadequate funding for healthcare has a direct negative impact on life expectancy, mortality rates and morbidity. The failure of successive governments to recognize the significance of the healthcare policy resulted in the increased financial burden for the patients and difficult access to treatment. However, with appropriate investment in healthcare, we can anticipate better life expectancy and decreased morbidity.

15.15 – 16.15

History of Market and Patient Access in Slovakia – lessons to learn?

Martin Višňanský

Over the last three decades Slovakia made improvements in modernizing health care system and policies by rapidly adopting new methods, medications and innovative health technologies. However, despite these improvements, Slovakia still faces significant challenges in the functioning and organization of their health systems: lack of resources, health technology assessment (HTA) implementation, lack of personnel, etc. What are the milestones of Market and Patient Access in Slovakia in reflecting this development?

SPEAKERS

Dominik Tomek



Director, ISPOR board of directors, 2014-2016
Board member, European Patients Forum board, 2012 –
Vice-president, Association for Patients' Rights Protection in Slovakia

Dr. Dominik Tomek, PharmD., PhD., MPH, 1956, has experience in public and hospital pharmacies, government administration and regulatory agency incl. oncology hospital, Ministry of Health and Health Insurance. He is a founding member of the Slovak Society for Pharmacoeconomics, Slovak Agency for Health Technology Assessment and a founding member and the current president of ISPOR Chapter Slovakia. He was elected as director in the ISPOR Board of Directors for the term 2014 – 2016 and board member of ISPOR CEE Network. Dr Tomek served for many years in the Drug Committee of State Institute for Drug Control, Pricing Committee of Ministry of Finance and Reimbursement Committee of Ministry of Health. He is teaching at the Faculty of Medicine, Slovak medical university, Bratislava, Slovakia. He studied Market Access at the University of Lyon with Prof Mondher Toumi in EMAUD class. He pioneered Patient Empowerment and patient education in Slovakia. Since 2010 he is teaching, training and lecturing patients in the field of treatment adherence, prevention, communication, health economy and other drug policy and health policy issues. He initiated patient education on the Faculty of Medicine, where he is supervising this education. As a patient himself, a patient relative and a long time health care provider, he is a dedicated patient advocate. He is vice president and scientific advisor to the Association for the Protection of Patient Rights in Slovak republic and Board Member of the European Patients Forum in Brussels.

Tamás Ágh



Principal researcher of Syreon Research Institute and Head of Business Development since 2016

Tamás Ágh MD MSc PhD is a principal researcher of Syreon Research Institute and Head of Business Development since 2016. With more than 8 years of experience in health economics research, he developed expertise in the fields of patient reported outcomes, health technology assessment, and health policy. Dr. Ágh has 10 years of experience as a medical doctor, specialized in family medicine. He is a part time university lecturer and module leader at Eötvös Loránd University (MSc in Health Policy, Finance and Analysis) in the field of Patient Reported Outcomes. Dr. Ágh is member of the leadership group of the ISPOR Multiple Medication Adherence Measurement Working Group, leader of the ISPOR CEE Network Patient Adherence/ Real World Outcomes Working Group, and member of the Board of Supervisors of the Hungarian Health Economics Association/ISPOR Hungary Chapter.

Nicola Bedlington



EPF's Secretary General since September 2014

Nicola Bedlington is EPF's Secretary General since September 2014 and was previously the Executive Director since the setting up of the EPF Secretariat in June 2006. She worked as an external expert for the European Commission on disability policy and NGO cooperation and was the first Director of the European Disability Forum during the 90s. More recently she led the ENSI Secretariat, an OECD initiated international governmental network on education and sustainable development.

Stanimir Hasurdjiev



Secretary General of the Patient Access Partnership
Chairperson, Bulgarian National Patients Organization (NPO)

Dr. Stanimir Hasurdjiev is one of the founders and current Chairperson of the Bulgarian National Patients' Organization (NPO) – the biggest patients' umbrella organization in Bulgaria. Dr. Hasurdjiev has over a decade of experience in working with patients and advocacy work in the patient movement. In 2011 and 2015, he represents the Bulgarian patients in the Supervisory Board of the National Health Insurance Fund. Dr. Hasurdjiev is also the Chairperson of the National Association for Fighting Hepatitis "Hepasist". As of May 2013, Dr. Hasurdjiev is a board member of the European Patients' Forum as well as a member of several other regional and international organizations and networks, e.g. World Hepatitis Alliance, European Community Advisory Board, International Capacity Building Alliance and others. He is one of the initiators and founding members of the joint initiative of the European Patients' Forum and the Bulgarian National Patients' Organization – the Patient Access Partnership – a multi stakeholder platform for finding innovative solutions to reduce inequities in access to healthcare in Europe.

Since March 2015, Dr. Hasurdjiev serves as a Secretary of the National “Health Partnership” - a permanent consultative body to the Bulgarian Council of Ministers which gathers together all stakeholders in health. As of March 2016, he is as a Secretary of the CEE Think Tank on Patient Access - an initiative that brings together experts, medical doctors, pharmacoeconomists, and representatives from patient associations from the CEE region.

Martin Visnansky



Martin Visnansky is current president of Slovak Society of Pharmacoeconomics

Martin Visnansky is a co-founder and current president of Slovak Society of Pharmacoeconomics. He has earned his MSc in Clinical Pharmacy, PharmD in Pharmaceutical Management and PhD in Corporate Management from Comenius University, Bratislava, Slovakia. On top of that he has obtained MBA from University of Pittsburgh, USA and MSc in HTA & Health Management from Universita Cattolica, Roma, Italy. He has more than 20 years of management and consulting experience in healthcare and pharmaceuticals, working for pharma (Novartis, Boehringer and Chiesi), private equity groups and the Government. He has served as an advisor to three Ministers of Health for drug policies and pharmacoeconomics. He is the co-founder of Slovak Agency for HTA (SLOVAHTA), current ISPOR Local Chapter Slovakia president-elect, lecturer/teacher at the University of veterinary medicine and human pharmacy pre-graduate MSc program and co-owner of several small-size healthcare providers.



FEZ – Financie, Ekonomika, Zdravotníctvo spol. s.r.o.
Vlčkova 49, 811 04, Bratislava

office@marketaccess.sk
www.marketaccess.sk
+421903186343